Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2 / Neha Upadhyay, Kalpana Tilekar, Sabreena Safuan, Alan P Kumar, Markus Schweipert, Franz-Josef Meyer-Almes, CS Ramaa
Background:Angiogenesis deregulation is often linked to cancer and is thus an essential target.Materials & methods:Twenty-nine compounds were developed as VEGFR-2 inhibitors. Compounds were evaluated to determine their antiangiogenic activity.Results:B1, PB11 and PB16 showed HUVEC's IC50 scores in the submicromolar range. B1, B2 and PB16 reduced cellular migration and capillary tube formation of HUVECs. VEGFR-2 inhibitory activity was found in the nanomolar range: 200 nM of B1, 500 nM of B2 and 600 nM of PB16. B1 and PB16 suppressed the formation of new capillaries on growing CAMs. B1 and PB16 occupied the ATP site and allosteric pocket of VEGFR-2 in docking studies.Conclusion:These compounds can target VEGFR-2 and are endowed within vitroandin vivoantiangiogenic activity. Background: Materials & methods: Results: 50 Conclusion: in vitro in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2021 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Upadhyay, Neha [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Umfang: |
1 Online-Ressource (24 p) |
|---|
| doi: |
10.4155/fmc-2021-0139 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011088168 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011088168 | ||
| 003 | DE-627 | ||
| 005 | 20230713210614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2021-0139 |2 doi | |
| 035 | |a (DE-627)KFL011088168 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/fmc-2021-0139 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Upadhyay, Neha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development and investigation of thiazolidinedione and pyrazoline compounds as antiangiogenic weapons targeting VEGFR-2 |c Neha Upadhyay, Kalpana Tilekar, Sabreena Safuan, Alan P Kumar, Markus Schweipert, Franz-Josef Meyer-Almes, CS Ramaa |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2021 | |
| 300 | |a 1 Online-Ressource (24 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background:Angiogenesis deregulation is often linked to cancer and is thus an essential target.Materials & methods:Twenty-nine compounds were developed as VEGFR-2 inhibitors. Compounds were evaluated to determine their antiangiogenic activity.Results:B1, PB11 and PB16 showed HUVEC's IC50 scores in the submicromolar range. B1, B2 and PB16 reduced cellular migration and capillary tube formation of HUVECs. VEGFR-2 inhibitory activity was found in the nanomolar range: 200 nM of B1, 500 nM of B2 and 600 nM of PB16. B1 and PB16 suppressed the formation of new capillaries on growing CAMs. B1 and PB16 occupied the ATP site and allosteric pocket of VEGFR-2 in docking studies.Conclusion:These compounds can target VEGFR-2 and are endowed within vitroandin vivoantiangiogenic activity. Background: Materials & methods: Results: 50 Conclusion: in vitro in vivo | ||
| 653 | |a antiangiogenic | ||
| 653 | |a diaryl-pyrazoline | ||
| 653 | |a thiazolidinedione | ||
| 653 | |a VEGFR-2 | ||
| 700 | 1 | |a Tilekar, Kalpana |e verfasserin |4 aut | |
| 700 | 1 | |a Safuan, Sabreena |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Alan P |e verfasserin |4 aut | |
| 700 | 1 | |a Schweipert, Markus |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer-Almes, Franz-Josef |e verfasserin |4 aut | |
| 700 | 1 | |a Ramaa, CS |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d London : Future Science, 2009 |h Online-Ressource |w (DE-627)KFL000006157 |w (DE-600)2572258-X |w (DE-576)398101442 |x 1756-8927 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/fmc-2021-0139 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||